Acquired severe aplastic anaemia (SAA) has an immune pathogenesis, and
immunosuppressive therapy (IST) with anti‐thymocyte globulin and cyclosporine is effective …

Background Acquired aplastic anemia (AAA) in pediatric patients is a rare disorder
characterized by hypocellular bone marrow and pancytopenia. Eltrombopag, an oral …

Eltrombopag is being investigated for the treatment of aplastic anemia (AA) by stimulating
hematopoietic stem cell (HSC) proliferation. To evaluate the efficacy and safety of …

Background Eltrombopag (EPAG), an oral thrombopoietin receptor agonist (TPO-RA), has
been proven to improve the hematologic response without increasing toxic effects as a first …

Background Severe aplastic anemia (SAA) is caused by immune-mediated destruction.
Standard immunosuppressive therapy (IST) is effective but needs to be improved. Methods …

Eltrombopag was approved as a first‐line treatment for patients older than 2 years old with
severe aplastic anemia (SAA). However, data on eltrombopag in children with different types …

Eltrombopag is used with first-line immunosuppressive therapy for adult aplastic anemia,
although its practical utility in childhood remains unclear. We retrospectively analyzed the …

3. Results A total of 9 patients were included (age at diagnosis range from 3 y/o∼ 16 y/o,
mean: 8 y/o). One patient was excluded from 9 patients for proceeding to HSCT within 1 …

Aplastic anemia (AA) is a hematological disease characterized by pancytopenia and
hypofunctional bone marrow hematopoiesis. Patients with AA are treated with either …

Aim: To evaluate the differences of efficacy and survival between adults and children
patients with severe aplastic anemia receiving intensive immunosuppressive therapy …